Case series of BRAF-mutated advanced melanoma treated with encorafenib plus binimetinib combination therapy

Taku Fujimura, Koji Yoshino, Hiroshi Kato, Yasuhiro Fujisawa, Yoshiyuki Nakamura, Yuki Yamamoto, Kayo Kunimoto, Takamichi Ito, Shigeto Matsushita, Takeo Maekawa, Kentaro Ohuchi, Ryo Amagai, Yusuke Muto, Sadanori Furudate, Yumi Kambayashi, Akira Hashimoto, Setsuya Aiba

研究成果: Contribution to journalArticle査読

抄録

The efficacy of encorafenib plus binimetinib (E + B) combination therapy for BRAF-mutated advanced melanoma as second-line therapy and beyond is still unknown. In this report, we investigated 22 cases of BRAF-mutated advanced melanoma treated with E + B combination therapy. The objective response rate (ORR) for the total cohort was 68.4%. Notably, the ORR for the second-line and beyond cohort was 73.3%, suggesting that the therapeutic effect of E + B combination therapy is comparable with that of first-line targeted therapy. In contrast, overall survival and progress-free survival in our present cohort was worse than that in a previous clinical trial. Notably, although the incidence rate of severe adverse events was higher than that in a previous report, our present study suggested that E + B combination therapy is a well-tolerated antimelanoma regimen. Our present study suggested that the efficacy and safety profile of E + B combination therapy as a second-line therapy and beyond is comparable with that of first-line targeted therapy.

本文言語英語
ページ(範囲)397-400
ページ数4
ジャーナルJournal of Dermatology
48
3
DOI
出版ステータス出版済み - 3 2021

All Science Journal Classification (ASJC) codes

  • 皮膚病学

フィンガープリント

「Case series of BRAF-mutated advanced melanoma treated with encorafenib plus binimetinib combination therapy」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル